Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$108.31
+1.2%
$105.79
$90.39
$212.75
$23.44B0.783.06 million shs352,318 shs
Moderna, Inc. stock logo
MRNA
Moderna
$58.70
-1.3%
$58.00
$22.28
$85.60
$23.35B0.949.05 million shs1.05 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$79.58
+2.0%
$76.80
$43.17
$90.87
$6.60B0.531.47 million shs308,061 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.57
+1.5%
$31.78
$10.90
$37.00
$24.82B1.115.98 million shs435,628 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-1.20%-1.94%+11.83%-24.09%+4.35%
Moderna, Inc. stock logo
MRNA
Moderna
-3.77%-11.22%-6.99%+9.70%+90.31%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-0.74%-4.08%-1.23%+10.45%+63.78%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.33%-1.33%+8.34%+16.25%+197.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$108.31
+1.2%
$105.79
$90.39
$212.75
$23.44B0.783.06 million shs352,318 shs
Moderna, Inc. stock logo
MRNA
Moderna
$58.70
-1.3%
$58.00
$22.28
$85.60
$23.35B0.949.05 million shs1.05 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$79.58
+2.0%
$76.80
$43.17
$90.87
$6.60B0.531.47 million shs308,061 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.57
+1.5%
$31.78
$10.90
$37.00
$24.82B1.115.98 million shs435,628 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-1.20%-1.94%+11.83%-24.09%+4.35%
Moderna, Inc. stock logo
MRNA
Moderna
-3.77%-11.22%-6.99%+9.70%+90.31%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-0.74%-4.08%-1.23%+10.45%+63.78%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.33%-1.33%+8.34%+16.25%+197.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
2.96
Moderate Buy$209.1393.09% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.82
Reduce$40.00-31.86% Downside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.80
Moderate Buy$92.2915.96% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-2.83% Downside

Current Analyst Ratings Breakdown

Latest PTCT, ROIV, MRNA, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$49.00 ➝ $67.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Initiated CoverageOutperform$192.00
7/20/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$220.00
7/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingUnderperform$25.00
7/20/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Lower Price TargetOverweight$95.00 ➝ $93.00
7/17/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingSell (D-)
7/16/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Boost Price TargetOverweight$124.00 ➝ $130.00
7/15/2026
Insmed, Inc. stock logo
INSM
Insmed
Boost Price TargetOverweight$160.00 ➝ $161.00
7/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy$207.00
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$606.42M38.71N/AN/A$3.46 per share31.30
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B11.98N/AN/A$22.14 per share2.65
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B3.81$8.89 per share8.95($2.56) per share-31.09
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,010.31N/AN/A$7.35 per share4.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A180.51N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$2.33N/A32.754.72-22.58%-362.45%-6.76%7/30/2026 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)

Latest PTCT, ROIV, MRNA, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33N/AN/AN/A$2.07 millionN/A
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.70N/AN/AN/A$392.53 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.0355N/AN/AN/A$103.10 millionN/A
7/30/2026Q2 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.2149N/AN/AN/A$295.38 millionN/A
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/7/2026Q1 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
2.44
2.36
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41082.95 million78.39 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Insmed stock logo

Insmed NASDAQ:INSM

$108.31 +1.29 (+1.20%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$58.70 -0.79 (-1.32%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$79.58 +1.57 (+2.02%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$34.57 +0.52 (+1.53%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.